Sam Ghoubrial
Internal Medicine · Wadsworth, OHNPI 1003892217
Payments from drug & device makers
Across 104 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$336
- Lilly USA, LLC$118
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
- Otsuka America Pharmaceutical, Inc.$85
- Novo Nordisk$83
- Biohaven Pharmaceutical Holding Company Ltd.$77
- plus $792 from 25 others
What the payments were for
- Food & beverage$1,582100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $336 |
| Lilly USA, LLC | 8 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Novo Nordisk | 6 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 5 | $75 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| AstraZeneca | 4 | $54 |
| Pfizer | 4 | $52 |
| Astellas Pharma US Inc | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Boehringer Ingelheim | 3 | $41 |
| Kyowa Kirin, Inc. | 3 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Novartis | 2 | $31 |
| GSK | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Inogen, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Bayer | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| UCB, Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$1,582 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 32 | $554 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $330 |
| Rosuvastatin Calcium | 15 | $312 |
| Atorvastatin Calcium | 16 | $212 |
| Allopurinol | 11 | $137 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Wadsworth
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.